This is the authors' abstract. We don't add key points for this paper.
The immune deregulation and disease-modifying anti-rheumatic drugs (DMARDs) make patients with autoimmune rheumatic diseases (ARD) more susceptible to infection. We aimed to investigate the prevalence and clinical outcome of COVID-19 in ARD patients with different treatments. PubMed, Embase, Medline, Cochrane Library, Web of Science were searched to identify the relevant evidence up to March 20, 2023. The overall prevalence of COVID-19 in ARD patients was 0.061. The ARD patients with glucocorticoids (GC) treatment had the highest prevalence[0.088(95%CI:0.065-0.110)] compared to biological (b) DMARDs[0.041(95%CI:0.031-0.051)], conventional synthetic (cs) DMARDs[0.055(95%CI:0.043-0.067)], and anti-TNF therapy[0.029(95%CI:0.003-0.056)]. In contrast, those receiving anti-TNF therapy had the lowest prevalence. The overall hospitalization rate, ICU admission rate, and mortality of ARD patients due to COVID-19 were 0.402(95%CI:0.330-0.476), 0.077(95%CI:0.051-0.107), and 0.073(95%CI:0.046-0.104). Using bDMARDs had lower hospitalization rates[0.216(95%CI:0.147-0.286)], ICU admission rates[0.010(95%CI:0.000-0.037)], and mortality[0.039(95%CI:0.007-0.087)]. Regression analysis showed a significant negative relationship between bDMARDs monotherapy and ICU admission rates(regression coefficient:-0.156, 95%CI:-0.260 - -0.051, P=0.006). Patients using csDMARDs had higher hospitalization rates[0.607(95%CI:0.450-0.755)], ICU admission rates[0.055(95%CI:0.037-0.075)], and mortality[0.074(95%CI:0.041-0.114)]. Patients using GC had a higher hospitalization rate[0.703(95%CI:0.449-0.910)], higher ICU admission rate[0.094(95%CI:0.046-0.152)], and lower mortality[0.070(95%CI:0.033-0.114)]. Regression analysis showed a significant positive correlation between GC monotherapy and hospitalization(regression coefficient:0.484, 95%CI:0.146-0.822, P=0.006). For ARD patients, csDMARDs were associated with disease severity in COVID-19, bDMARDs were associated with a reduced risk of severe disease, and GC was effective in patients with severe COVID-19-related respiratory failure.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Su et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: